Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.

Immuron (IMRN) Competitors

Immuron logo

IMRN vs. XCUR, PRLD, ALRN, BIVI, RFL, NBRV, VIRI, GANX, SCYX, and RLYB

Should you be buying Immuron stock or one of its competitors? The main competitors of Immuron include Exicure (XCUR), Prelude Therapeutics (PRLD), Aileron Therapeutics (ALRN), BioVie (BIVI), Rafael (RFL), Nabriva Therapeutics (NBRV), Virios Therapeutics (VIRI), Gain Therapeutics (GANX), SCYNEXIS (SCYX), and Rallybio (RLYB). These companies are all part of the "pharmaceutical preparations" industry.

Immuron vs.

Exicure (NASDAQ:XCUR) and Immuron (NASDAQ:IMRN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, community ranking, dividends, media sentiment, risk, valuation and institutional ownership.

Immuron received 179 more outperform votes than Exicure when rated by MarketBeat users. Likewise, 67.87% of users gave Immuron an outperform vote while only 47.37% of users gave Exicure an outperform vote.

CompanyUnderperformOutperform
ExicureOutperform Votes
9
47.37%
Underperform Votes
10
52.63%
ImmuronOutperform Votes
188
67.87%
Underperform Votes
89
32.13%

Immuron has higher revenue and earnings than Exicure.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Exicure$500K97.31-$16.91M-$2.07-9.02
Immuron$3.21M3.50-$4.55MN/AN/A

Exicure has a beta of 3.66, suggesting that its share price is 266% more volatile than the S&P 500. Comparatively, Immuron has a beta of 1.35, suggesting that its share price is 35% more volatile than the S&P 500.

Immuron has a consensus price target of $5.00, suggesting a potential upside of 155.10%. Given Immuron's stronger consensus rating and higher possible upside, analysts clearly believe Immuron is more favorable than Exicure.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Exicure
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Immuron
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Immuron's return on equity of 0.00% beat Exicure's return on equity.

Company Net Margins Return on Equity Return on Assets
ExicureN/A -190.90% -36.75%
Immuron N/A N/A N/A

In the previous week, Exicure had 6 more articles in the media than Immuron. MarketBeat recorded 6 mentions for Exicure and 0 mentions for Immuron. Exicure's average media sentiment score of 0.15 beat Immuron's score of 0.00 indicating that Exicure is being referred to more favorably in the media.

Company Overall Sentiment
Exicure Neutral
Immuron Neutral

42.8% of Exicure shares are held by institutional investors. Comparatively, 0.1% of Immuron shares are held by institutional investors. 3.9% of Exicure shares are held by company insiders. Comparatively, 7.0% of Immuron shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Immuron beats Exicure on 10 of the 15 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IMRN vs. The Competition

MetricImmuronPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$11.23M$6.57B$5.14B$9.08B
Dividend YieldN/A2.99%5.09%4.23%
P/E RatioN/A10.5990.0517.18
Price / Sales3.50196.061,116.25117.05
Price / CashN/A57.1643.1037.85
Price / Book1.345.094.784.78
Net Income-$4.55M$151.83M$120.31M$225.60M

Immuron Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IMRN
Immuron
2.1279 of 5 stars
$1.96
-1.8%
$5.00
+155.1%
+0.5%$11.23M$3.21M0.00N/A
XCUR
Exicure
0.88 of 5 stars
$18.35
+6.0%
N/A+3,130.1%$47.89M$28.83M-9.2750News Coverage
Gap Up
PRLD
Prelude Therapeutics
2.9419 of 5 stars
$0.86
+7.5%
$4.00
+365.0%
-68.0%$47.34MN/A-0.52120News Coverage
Positive News
Gap Up
High Trading Volume
ALRN
Aileron Therapeutics
3.0747 of 5 stars
$2.16
-4.4%
$19.00
+779.6%
-41.9%$46.81MN/A-0.729Positive News
BIVI
BioVie
1.1579 of 5 stars
$2.63
-0.4%
$3.00
+14.1%
+53.2%$46.73MN/A-0.2310
RFL
Rafael
0.7384 of 5 stars
$1.89
+0.3%
N/A+7.1%$46.54M$640,000.00-1.1313Gap Up
NBRV
Nabriva Therapeutics
N/AN/AN/AN/A$45.46M$35.59M-0.0739Analyst Forecast
VIRI
Virios Therapeutics
N/A$2.36
-2.1%
$3.00
+27.1%
+300.7%$45.45MN/A-8.745
GANX
Gain Therapeutics
2.6702 of 5 stars
$1.63
flat
$7.25
+344.8%
-37.6%$43.24M$50,000.00-1.4820
SCYX
SCYNEXIS
0.8192 of 5 stars
$1.13
-0.9%
N/A-46.5%$42.88M$8.57M-1.5460Gap Down
RLYB
Rallybio
2.6942 of 5 stars
$1.03
-4.5%
$9.75
+845.3%
-63.6%$42.79MN/A-0.6740

Related Companies and Tools


This page (NASDAQ:IMRN) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners